Pennsylvania Senate Bill SB301

Pennsylvania 2025-2026 Regular Session

• Introduced: 2/25/25
• Refer: 2/25/25

Caption

Providing for price disclosure.

Impact

If enacted, SB301 will directly affect consumer interactions with pharmacies across the Commonwealth. Pharmacies will be obliged to inform customers about the costs associated with their medications and provide necessary documentation to ensure compliance. Furthermore, this bill could influence pricing strategies within pharmacies as they adjust to the public demand for transparency. The legislation intends to create a more equitable environment for drug pricing and potentially alleviate costs for consumers by ensuring they receive the necessary information to make better healthcare choices.

Summary

Senate Bill 301, introduced in Pennsylvania, amends the Pharmacy Act to mandate price disclosures for prescription medications. This bill requires pharmacies to disclose the retail price of both brand-name and generically equivalent drugs upon consumer request. Additionally, it specifies the need to inform consumers about their cost-sharing amounts and offers guidance on how to apply for subsidized health coverage through the state's health insurance exchange. The ultimate goal of SB301 is to enhance transparency in drug pricing, allowing consumers to make informed decisions regarding their healthcare expenditures.

Sentiment

The sentiment surrounding SB301 is largely positive, particularly among consumer advocacy groups and health policy makers. Supporters argue that the increased transparency will empower consumers, enabling them to understand the real costs of their prescriptions and compare options effectively. However, there is some concern regarding the additional burden placed on pharmacies, especially smaller establishments that may struggle to comply with new regulations without significant changes to their operations.

Contention

Notable points of contention include the potential impact of these requirements on pharmacy operations. Critics argue that although transparency is beneficial, the additional administrative tasks could strain resources and disproportionately affect smaller pharmacies that are less equipped to handle such demands. Additionally, the effectiveness of this legislation in substantially lowering prescription costs remains to be seen, as some skeptics question how much information disclosure alone can genuinely influence pricing behavior from pharmaceutical companies and insurance providers.